Atlas Trials

Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Clinical trial NCT04503694 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04503694
Sponsor
Jules Bordet Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Rectal Cancer Stage IIRectal Cancer Stage III
Start date
2021-03-25
Primary completion
2026-12-31
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.